Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SaMe) infusions in elderly subjects, utilizing EEG mapping and psychometry

Journal of Neural Transmission

Volumn 109, Issue 12, 2002, Pages 1505-1526

  Saletu, Bernd ^a   Anderer, P ^a   Linzmayer, L ^a   Semlitsch, H V ^a   Lindeck Pozza, E ^a   Assandri, A ^b   Di Padova, C ^c   Saletu Zyhlarz, G M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Cross Research   (Switzerland)

^c Knoll Farmaceutici SPA   (Italy)

Author keywords

Antidepressant; Elderly subjects; Good tolerability; Pharmaco EEG; Psychometry; S adenosyl L methionine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; IMIPRAMINE; NOOTROPIC AGENT; PLACEBO; S ADENOSYLMETHIONINE;

ADULT; AGED; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN MAPPING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; INFUSION; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; NORMAL HUMAN; PHARMACODYNAMICS; POWER SPECTRUM; PRIORITY JOURNAL; PSYCHOMETRY;

AGED; ANTIDEPRESSIVE AGENTS; BRAIN; CROSS-OVER STUDIES; DEPRESSION; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOMETRICS; S-ADENOSYLMETHIONINE;

EID: 0036921639     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-002-0768-6     Document Type: Article

References (97)

1. Abt K (1987) Descriptive data analysis: A concept between confirmatory and exploratory data analysis. Methods Inf Med 26: 77-88
2. Abt K (1988) Descriptive data analysis (DDA) in quantitative EEG studies. In: Samson-Dollfus D (ed) Statistics and Topography in Quantitative EEG. Elsevier, Paris
3. Abt K (1990) Statistical aspects of neurophysiologic topography. J Clin Neurophysiol 7(4): 519-534
4. Agnoli A, Andreoli V, Casacchia M, Cerbo R (1976) Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 13: 43-54
5. Algeri S, Catto E, Curcio M, Ponzio F, Stramentinoli GH (1979) Changes in rat brain noradrenaline and serotonin metabolism after administration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore S (eds) Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System. Pergamon Press, New York, pp 81-87
6. Anderer P, Saletu B, Kinsperger K, Semlitsch H (1987) Topographic brain mapping of EEG in neuropsychopharmacology, part I. Methodological aspects. Meth Find Exp Clin Pharmacol 9 (6): 371-384
7. Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ (1992) Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 45: 79-93
8. Anderer P, Saletu B, Pascual-Marqui RD (2000) Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man: A functional neuroimaging study using low-resolution electromagnetic tomography (LORETA). Psychiatry Res Neuroimaging 100: 81-96
9. Anderer P, Saletu B, Semlitsch HV, Assandri A, DiPadova C, Prause W, Lindeck-Pozza E, Saletu-Zyhlarz GM (2002) Acute and sub-acute, double-blind, placebo-controlled studies on the effects of S-adenosyl-L-methionine on information processing by ERP-mapping and LORETA. In: Hirata K (ed) Recent Advances in Human Brain Mapping. Elsevier, Amsterdam, pp 237-241
10. Baldessarini RJ (1987) Neuropharmacology of S-adenosyl-L-methionine. Am J Med 83 [Suppl 5A]: 95-103
11. Barberi A, Pusateri C (1978) Sugli effetti della S-adenosyl-metionina (SAMe) nelle sindromi depressive. Estratto da Minerva Psichiatrica 19: 235-243
12. Bell KM, Plon L, Bunney Jr WE, Potkin SG (1988) S-adenosyl-methionine treatment of depression: A controlled clinical trial. Am J Psychiatry 145: 1110-1114
13. Bottiglieri T, Chary TK, Laundy M, Carney MW, Godfrey P, Toone BK, Reynolds EH (1988) Transmethylation in depression. Alabama J Med Sci 25: 296-301
14. Bottiglieri T, Godfrey P, Flynn T, Carey MWP, Toone BK, Reynolds EH (1990) Cere-brospinal fluid S-adenosyl-methionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosyl-methionine. J Neurol Neurosurg Psychiatry 53: 1096-1098
15. Bressa GM (1994) S-adenosyl-L-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 154: 7-14
16. Buchsbaum MS, Hazlett E, Sicotte N, Stein M, Wu J, Zetin M (1985) Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder. Biol Psychiatry 20: 832-842
17. Carney MWP (1986) Review: Neuropharmacology of S-adenosyl-L-methionine. Clin Neuropharmacol 9: 235-243
18. Caruso I, Fumagalli M, Bocassini L, Sarzi Puttini P, Santandrea S, Volpato R, Locati M, Montrone F (1987) Treatment of depression in rheumatoid arthritic patients: A comparison of S-adenosyl-methionine (Samyr) and placebo in a double-blind study. Clin Trials J 24: 305-310
19. Chawla RK, Bonkovsky HL, Galambos JT (1990) Biochemistry and pharmacology of S-adenosyl-methionine and rationale for its use in liver disease. Drugs 40 [Suppl 3]: 91-110
20. Cimino S, Vantini G, Algeri S, Curatola G, Pezzoli C, Stramentinoli G (1984) Age-related modification of dopaminergic and β-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with S-adenosyl-methionine. Life Sci 34: 2029-2039
21. 1- and β-adrenoceptors in rat brain. Life Eur J Pharmacol 170: 201-207
22. Coiro V, Vescovi PP (1997) Controlled study of psychometric performance in abstinent alcoholics: Masked comparison of the effects of 15-day intravenous treatments with S-adenosylmethionine or normal saline. Curr Ther Res 58 (9): 575-586
23. Curcio M, Catto E, Stramentinoli G, Algeri S (1978) Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Prog Neuropsychopharmacol 2: 65-71
24. De Leo D (1985) S-adenosyl-L-methionine (SAMe) in clinical practice: Preliminary report on 75 depressives. Curr Ther Res 37: 658-661
25. Delle Chiaie R, Pancheri R, Scapicchio P (2001) Results of two multicentre, controlled efficacy and safety trials of oral (MC3) and intramuscular (MC4) s-adenosylmethionine (SAMe) vs. oral imipramine in the treatment of depression. Presented at the Oxygen Club of California's 2001 World Congress: Oxidants and Antioxidants in Biology, Santa Barbara, March 7-10, 2001
26. De Vanna M, Rigamonti R (1992) Oral S-adenosyl-L-methionine in depression. Curr Ther Res 52: 478-485
27. Del Vecchio M, Iorio G, Cocorullo M, Vacca L, Amati A (1978) Has SAMe an anti-depressant effect? A preliminary trial versus chlorimipramine. Rivista Sperimentale di Freniatria 102: 344-358
28. 3H]-GABA binding in membrane preparations of rat cerebellum. J Neurochem 41: 302-308
29. Duffy FH, Bartels PH, Burchfield JL (1981) Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 51: 455-462
30. Fazio C, Andreoli V, Agnoli A, Casachia M, Cerbo R (1973) Effetti terapeutici e meccanismo d'azione della S-adenosil-L-metionina (SAM) nelle sindromi depressive. Minerva Medica 64: 1515-1529
31. Fink M (1975) Cerebral electrometry - Quantitative EEG applied to human psychopharmacology. In: Dolce G, Künkel H (eds) Computerized EEG Analysis. Fischer, Stuttgart, pp 271-288
32. Friedel HA, Goa KL, Benfield P (1989) S-adenosyl-L-methionine: Review of its pharmacological properties and therapeutical potential liver disfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38 [Suppl 3]: 389-416
33. Grünberger J (1977) Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Maudrich, Wien
34. Grünberger J, Saletu B (1980) Determination of pharmacodynamics of psychotropic drugs by psychometric analysis. Prog Neuropsychopharmacol Biol Psychiatry 4: 417-434
35. Grünberger J, Linzmayer L, Saletu B (1984) Klinische psychodiagnostik mit hilfe psychophysiologischer verfahren (Clinical psychodiagnostics by means of psychophysiological techniques). Wien Med Wochenschr 134: 29-35
36. Grünberger J, Linzmayer L, Dietzl M, Saletu B (1993) The effect of biologically active light on the noo- and thymopsyche and on psychophysiological variables in healthy volunteers. Int J Psychophysiol 15: 27-37
37. Halgren E, Baudena P, Clarke JM, Heit G, Liégois C, Chauvel P, Musolino A (1995) Intracerebral potentials to rare target and distractor auditory and visual stimuli. I. Superior temporal plane and parietal lobe. Electroencephalogr Clin Neurophysiol 94: 191-220
38. Herrmann WM (1982) Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In: Herrmann WM (ed) Electroencephalography in Drug Research. Gustav Fischer, Stuttgart New York, pp 249-351
39. Herrmann WM, Schärer E (1986) Das pharmako-EEG und seine bedeutung für die klinische pharmakologie. In: Kuemmerle HP, Hitzenberger G, Spitzy KH (eds) Klinische Pharmakologie, 4th Ed. Landsberg, München, pp 1-71
40. Hirata F, Axelrod J (1980) Phospholipid methylation and biological signal transmission. Science 209: 1082-1090
41. Hyman SE, Nestler EJ (1996) Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151-162
42. Itil TM (1974) Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: Itil TM (ed) Psychotropic Drugs and the Human EEG. Karger, Basel, pp 43-75 (Mod Probl Pharmacopsychiatry)
43. Itil TM, Shapiro DM, Eralp E, Akmann A, Itil KZ, Garbizu C (1985) A new brain function diagnostic unit, including the dynamic brain mapping of computer analyzed EEG, evoked potentials and sleep (a new hardware/software system and its application in psychiatry and psychopharmacology). New Trends Exp Clin Psychiatry 1: 107-177
44. Janicak PG, Lipinski J, Davis JM, Comaty JE, Waternaux C, Cohen B, Altman E, Sharma RP (1988) S-adenosyl-methionine in depression: A literature review and preliminary report. Alabama J Med Sci 25 (3): 306-331
45. John ER, Prichep LS, Fridman J, Easton P (1988) Neurometrics: Computer-assisted differential diagnosis of brain dysfunctions. Science 239: 162-169
46. Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH (1990) Oral S-adenosyl-L-methionine in depression: A double-blind, placebo-controlled trial. Am J Psychiatry 147: 591-595
47. Küfferle B, Grünberger J (1982) Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. In: Costa E, Racagni G (eds) Typical and Atypical Antidepressants: Clinical Practice. Raven Press, New York, pp 175-180
48. Lehmann D (1989) From mapping to the analysis and interpretation of EEG/EP maps. In: Maurer K (ed) Topographic Brain Mapping of EEG and Evoked Potentials. Springer, Berlin Heidelberg New York Tokyo, pp 53-75
49. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B, Harris P (1984) Open trial of S-adenosyl-methionine for treatment of depression. Am J Psychiatry 141(3): 448-450
50. Macher JP (1995) Effects of 800, 1600 and 2400mg Ademetionine and Placebo on Nocturnal Sleep and on Pharmaco-EEG Parameters of Young Healthy Volunteers After Multiple Oral Dosing. Forenap, Rouffach (unpublished report)
51. Mantero M, Pastorino P, Carolei A, Agnoli A (1975) Controlled double-blind study (SAMe-imipramine) in depressive syndromes (Studio controllato in doppio cieco (SAMe-Imipramina) nelle sindromi depressive). Estratto da Minerva Medica 66(78): 4098-4101
52. Maurer K, Dierks T (1991) Atlas of Brain Mapping. Topographic Mapping of EEG and Evoked Potentials. Springer, Berlin Heidelberg New York Tokyo
53. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT (1999) Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatry 156(5): 675-682
54. Miccoli L, Porro V, Bertolino A (1978) Comparison between the antidepressant activity of S-adenosyl-methionine (SAMe) and that of some tricyclic drugs. Estratto da Acta Neurologica 33(3): 243-255
55. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R (1992) Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 227: 293-299
56. Muscettola G, Galzenati M, Balbi A (1982) Same versus placebo: A double-blind comparison in major depressive disorders. In: Costa E, Racagni G (eds) Typical and Atypical Antidepressants: Clinical Practice. Raven Press, New York, pp 151-156
57. Otero-Losada ME, Rubio MC (1989) Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. Gen Pharmac 20: 403-406
58. Pancheri P, Racagni G, delle Chiaie R, Popoli M (1997) Nuove acquisizioni sperimentali e cliniche sulla efficacia e tollerabilità della ademetionina come antidepressivo. Giornale Italiano di Psicopatologia 3(2): 1-23
59. Pascual-Marqui RD, Michel CM, Lehmann D (1994) Low resolution electromagnetic tomography: A new method for localizing electrical activity in the brain. Int J Psychophysiol 18: 49-65
60. Rosenbaum JF, Fava M, Falk WE, Pollak MH, Cohen LS, Cohen BM, Zubenko GS (1990) The antidepressant potential of oral S-adenosyl-methionine. Acta Psychiatr Scand 81(5): 432-436
61. Saletu B (1976) Psychopharmaka, Gehirntätigkeit und Schlaf. Karger, Basel
62. Saletu B (1982) Pharmaco-EEG profiles of typical and atypical antidepressants. In: Costa E, Racagni G (eds) Typical and Atypical Antidepressants: Clinical Practice. Raven Press, New York, pp 257-268
63. Saletu B (1987) The use of pharmaco-EEG in drug profiling. In: Hindmarch I, Stonier PD (eds) Human Psychopharmacology, Measures and Methods, vol 1. John Wiley & Sons, Chichester New York Brisbane Toronto Singapore, pp 173-200
64. Saletu B (1997) Visualizing the living human brain. The techniques and promise of EEG and event-related potentials mapping. In: Judd L, Saletu B, Filip V (eds) Basic and Clinical Science of Mental and Addictive Disorders. Karger, Basel, pp 54-62 (Bibliotheca Psychiatrica 167)
65. Saletu B (2000) Pharmacodynamics and EEG. I. From single-lead pharmaco-EEG to EEG mapping. In: Saletu B, Krijzer F, Ferber G, Anderer P (eds) Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. Facultas Universitätsverlag, Wien, pp 139-156
66. Saletu B, Grünberger J (1983) Zur klassifikation und objektivierung der pharmakodynamik der antidepressiva. In: Saletu B, Berner P (eds) Zyklothymie. Excerpta Medica, Amsterdam Geneva Hong Kong Oxford Princeton Tokyo, pp 103-126
67. Saletu B, Grünberger J (1985a) On acute and chronic CNS effects of antidepressant in normals: Neurophysiological, behavioral and pharmacokinetic studies with pirlindol. Meth Find Exp Clin Pharmacol 7: 137-151
68. Saletu B, Grünberger J (1985b) Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG and psychometric analyses. J Clin Psychiatry 46, 3 (Sec 2): 45-52
69. Saletu B, Saletu M, Itil TM (1973) Effect of tricyclic antidepressants on the somatosensory evoked potential in man. Psychopharmacologia (Berl) 29: 1-2
70. Saletu B, Grünberger J, Linzmayer L (1980a) Is amezinium metilsulfate - A new antihypotensive drug - Psychoactive? Comparative quantitative EEG and psychometric trials with desipramine and methamphetamine. Curr Ther Res 28: 800-826
71. Saletu B, Grünberger J, Linzmayer L, Anderer P (1980b) Classification and assessment of pharmacodynamics of SGD-SCHA 1059 (Binodaline) by quantitative EEG and psychometric analyses. In: Perris C, v Knorring L, Kemali D (eds) Clinical Neurophysiological Aspects of Psychopathological Conditions. Karger, Basel, pp 140-166 (Adv Biol Psychiatry, vol 4)
72. Saletu B, Grünberger J, Rajna P, Karobath M (1980c) Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: Quantitative EEG, psychometric and pharmacokinetic studies in man. J Neural Transm 49: 63-86
73. Saletu B, Grünberger J, Linzmayer L, Taeuber K (1982) The pharmacokinetics of nominfensine. Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG. Int Pharmacopsychiatry 17: 43-72
74. Saletu B, Grünberger J, Rajna P (1983) Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol 15: 369-384
75. Saletu B, Grünberger J, Linzmayer L (1985) Early clinical pharmacological studies with sercloremine - A novel antidepressant - Utilizing pharmacokinetic, pharmaco-EEG and psychometric analyses. Drug Dev Res 6: 19-38
76. Saletu B, Grünberger J, Linzmayer L (1986) On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm 67: 241-266
77. Saletu B, Anderer P, Kinsperger K, Grünberger J (1987a) Topographic brain mapping of EEG in neuropsychopharmacology, part II. Clinical applications (Pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 9(6): 385-408
78. Saletu B, Anderer P, Kinsperger K, Grünberger J, Musch B (1987b) On the central effects of the GABA agonist fengabine: Psychometric and pharmaco-EEG studies utilizing imaging methods. Drug Dev Res 11: 251-279
79. Saletu B, Küfferle B, Anderer P, Grünberger J, Steinberger K (1990) EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur Neuropsychopharmacol 1: 27-36
80. Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhof KP, Litschauer G (1991) EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Disord 5 [Suppl 1]: 57-75
81. Saletu B, Grünberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G (1992) Phar-macodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 33: 589-601
82. Saletu B, Brandstätter N, Metka M, Stamenkovic M, Anderer P, Semlitsch HV, Heytmanek G, Huber J, Grünberger J, Linzmayer L, Kurz Ch, Decker K, Binder G, Knogler W, Koll B (1996) Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas 23: 91-105
83. Saletu B, Anderer P, Pascual-Marqui R, Semlitsch HV (1997) EEG/ERP-mapping as a tool in psychopharmacology. Eur Neuropsychopharmacol 7(2S): 130S
84. Saletu B, Anderer P, Assandri A, Prause W, Hassan Abu-Bakr M, Lindeck-Pozza E, Saletu-Zyhlarz GM (2000) Proving central effects of the nutraceutical and supplementary substance S-adenosyl-L-methionine (ademetionine) by pharmaco-EEG mapping. In: Saletu B, Krijzer F, Ferber G, Anderer P (eds) Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. Facultas Universitätsverlag, Wien, pp 182-192
85. Saletu-Zyhlarz G, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder. 1. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 36: 117-129
86. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Gracie C (1993) Double-blind placebo-controlled study of S-adenosyl-L-methionine in depressed post-menopausal women. Psychother Psychosom 5: 34-40
87. Scaggion G, Baldan L, Domanin S, Sivo M, Cenci I, Beggio R, Castorina G (1982) Antidepressive action of S-adenosylmethionine compared to nomifensine maleate (Azione antidepressiva della SAMe a confronto con il nomifensine maleato). Estratto da Minerva Psichiatrica 23(2): 93-97
88. Scarzella R, Appiotti A (1978) Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Rivista Sperimentale di Freniatria 102: 344-358
89. Schuhfried G (1997) Wiener Reaktionstest, Version 3.00. Mödling
90. Sebban CL, Debouzy CL, Berthaux P (1984) EEG quantifie et cartographie numerise. In: Lassen NA, Cahn J (eds) Maladies et Medicaments/Drugs and Diseases. Libbey/Eurotext, London Paris, pp 176-181
91. Stramentinoli G (1987) Various pharmacological aspects of S-adenosylmethionine: An overview. Cell Biol Rev S1: 67-80
92. Tolbert LC (1988) MAT kinetics in affective disorders and schizophrenia: An account. Alabama J Med Sci 25: 291-296
93. Torta R, Borio R, Cicolin A, Vighetti S, Ravizza L (1994) S-adenosyl-L-methionine normalizes P300 latency in patients with major depression. Curr Ther Res 55: 864-874
94. Von Zerssen D (1971) Die beschwerden-liste als test. Therapiewoche 21: 1908-1914
95. Von Zerssen D (1976) Die Befindlichkeitsskala: Parallelformen Bf-S und Bf-S'. Beltz, Weinheim
96. Von Zerssen D, Koeller DM, Rey ER (1970) Die Befindlichkeitsskala (B-S): Ein einfaches instrument zur objektivierung von befindlichkeitsstörungen, insbesondere im rahmen von längsschnittuntersuchungen. Arzneimittelforschung/Drug Res 20: 915-918
97. Zanotti S, Mori S, Radaelli R, Perez J, Racagni G, Popoli M (1998) Modifications in brain cAMP- and calcium/calmodulin-dependent protein kinases induced by treatment with S-adenosylmethionine. Neuropharmacology 37: 1081-1089